$INKT News

B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript

MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary

MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...

MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research Symposium - Slideshow

MiNK Therapeutics Q2 Earnings Call Highlights

MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript

MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate

MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical Illness

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target